NASDAQ:ENTA

Enanta Pharmaceuticals (ENTA) Stock Price, News & Analysis

$12.13
-0.93 (-7.12%)
(As of 05/17/2024 ET)
Today's Range
$12.06
$13.02
50-Day Range
$12.13
$17.46
52-Week Range
$8.08
$28.25
Volume
267,890 shs
Average Volume
129,310 shs
Market Capitalization
$256.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00

Enanta Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Hold
2.17 Rating Score
Upside/​Downside
56.6% Upside
$19.00 Price Target
Short Interest
Bearish
14.15% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
-0.10mentions of Enanta Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($5.95) to ($4.99) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.25 out of 5 stars

Medical Sector

303rd out of 921 stocks

Pharmaceutical Preparations Industry

130th out of 418 stocks

ENTA stock logo

About Enanta Pharmaceuticals Stock (NASDAQ:ENTA)

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

ENTA Stock Price History

ENTA Stock News Headlines

Enanta Pharmaceuticals Inc
ENTA Enanta Pharmaceuticals, Inc.
ENTA Oct 2024 20.000 call
See More Headlines
Receive ENTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/20/2023
Today
5/18/2024
Next Earnings (Estimated)
8/05/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ENTA
Employees
145
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$19.00
High Stock Price Target
$27.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+56.6%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
6 Analysts

Profitability

Net Income
$-133,820,000.00
Net Margins
-180.76%
Pretax Margin
-178.25%

Debt

Sales & Book Value

Annual Sales
$72.88 million
Book Value
$7.84 per share

Miscellaneous

Free Float
18,290,000
Market Cap
$256.90 million
Optionable
Optionable
Beta
0.54
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

ENTA Stock Analysis - Frequently Asked Questions

Should I buy or sell Enanta Pharmaceuticals stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ENTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENTA, but not buy additional shares or sell existing shares.
View ENTA analyst ratings
or view top-rated stocks.

What is Enanta Pharmaceuticals' stock price target for 2024?

6 equities research analysts have issued 1-year price objectives for Enanta Pharmaceuticals' shares. Their ENTA share price targets range from $11.00 to $27.00. On average, they expect the company's share price to reach $19.00 in the next twelve months. This suggests a possible upside of 56.6% from the stock's current price.
View analysts price targets for ENTA
or view top-rated stocks among Wall Street analysts.

How have ENTA shares performed in 2024?

Enanta Pharmaceuticals' stock was trading at $9.41 at the start of the year. Since then, ENTA stock has increased by 28.9% and is now trading at $12.13.
View the best growth stocks for 2024 here
.

When is Enanta Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024.
View our ENTA earnings forecast
.

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) released its quarterly earnings data on Monday, November, 20th. The biotechnology company reported ($1.33) earnings per share for the quarter, beating analysts' consensus estimates of ($2.11) by $0.78. The biotechnology company earned $18.93 million during the quarter, compared to analyst estimates of $17.93 million. Enanta Pharmaceuticals had a negative net margin of 180.76% and a negative trailing twelve-month return on equity of 64.85%. During the same quarter last year, the firm posted ($1.27) earnings per share.

What ETF holds Enanta Pharmaceuticals' stock?

Amplify Treatments, Testing and Advancements ETF holds 4,991 shares of ENTA stock, representing 0.72% of its portfolio.

What is Jay R. Luly's approval rating as Enanta Pharmaceuticals' CEO?

5 employees have rated Enanta Pharmaceuticals Chief Executive Officer Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among the company's employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Enanta Pharmaceuticals to a friend.

What other stocks do shareholders of Enanta Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS).

Who are Enanta Pharmaceuticals' major shareholders?

Enanta Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.11%), Acadian Asset Management LLC (4.04%), Jacobs Levy Equity Management Inc. (0.92%), BNP Paribas Financial Markets (0.12%), Portland Global Advisors LLC (0.12%) and Russell Investments Group Ltd. (0.09%). Insiders that own company stock include Brendan Luu, Bruce L A Carter, Jay R Luly, Nathalie Adda, Paul J Mellett, Scott T Rottinghaus, Terry Vance and Yat Sun Or.
View institutional ownership trends
.

How do I buy shares of Enanta Pharmaceuticals?

Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ENTA) was last updated on 5/19/2024 by MarketBeat.com Staff

From Our Partners